Recruiting

Observational Study

Sponsor:

Wake Forest University Health Sciences

Code:

NCT06480591

Conditions

Myeloproliferative Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Blood Draw

Study Details

Brief summary:

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Conditions

Myeloproliferative Neoplasm

Study ID

NCT06480591

Start date

Jan 21, 2025

Status verified date

Jul, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
  • Age ≥ 18 years at the time of enrollment
  • Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
  • CALR-positive genetic mutation

Exclusion Criteria:

\- Diagnosis of MPN with JAK2 V617F mutation

Study Design

Enrollment

35 participants

Anticipated

Interventions and Outcome Measures

Arms

JAK2 V617F mutation positive MPN patients

Patients with MPN disease with a JAK2 mutation

CALR-mutation positive patients

Patients with MPN disease with a CALR mutation

Interventions

Blood Draw

The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.

Primary outcome measure

  • Expression levels of TLR 2 and TLR 4 [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Courtney Schepel

(980) 292-0817Courtney.Schepel@atriumhealth.org

Locations

Atrium Health Levine Cancer

Recruiting

Charlotte, North Carolina, United States, 28204

Contacts

Courtney Schepel

(980) 292-0817Courtney.Schepel@atriumhealth.org

Principal Investigator:

Aleksander Chojecki, MD

Wake Forest Baptist Comprehensive Cancer Center

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

Ruben Mesa, MD

336-716-4618ruben.mesa@atriumhealth.org

Principal Investigator:

Ruben Mesa, MD

More Information

Sponsor

Wake Forest University Health Sciences

Last update posted

Jul 13, 2026

Last verified

Jul, 2026

Keywords

  • Thrombosis
  • JAK2 mutation
  • CALR mutation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Wake Forest University Health Sciences on 2026-07-13.